Xenon Genetics Inc. completed a private placement of Series E preferred shares on March 26, 2001 for approximately $70 million. JP Morgan H&Q acted as the placement agent. This is the largest private placement ever made by an independent Canadian biotechnology company. The financing was placed with an international syndicate of institutional investors, venture capital firms and private investors. Xenon is a privately owned clinical genomics and drug discovery company engaged in identifying genes associated with human disease and developing pharmaceutical therapies based on these genetic targets.
Xenon Genetics Inc. was represented by Richard Balfour, Linda Brown and Darren Watt (corporate) of McCarthy Tétrault. Craig Wright, Elizabeth Walker, Natalie Gouthro, David Caplan and Christine Hicks of Osler, Hoskin & Harcourt LLP were counsel to the investors, and Jim Fulton and Sam Safai of Cooley Godward LLP’s San Francisco office acted for JP Morgan H&Q.
Xenon Genetics Inc. was represented by Richard Balfour, Linda Brown and Darren Watt (corporate) of McCarthy Tétrault. Craig Wright, Elizabeth Walker, Natalie Gouthro, David Caplan and Christine Hicks of Osler, Hoskin & Harcourt LLP were counsel to the investors, and Jim Fulton and Sam Safai of Cooley Godward LLP’s San Francisco office acted for JP Morgan H&Q.
Lawyer(s)
Linda G. Brown
Elizabeth M. Walker
Richard J. Balfour
Sharon Snooks
J. Craig Wright
Christine E. Hicks
Jim F. Fulton
Firm(s)
McCarthy Tétrault LLP
Osler, Hoskin & Harcourt LLP
Osler, Hoskin & Harcourt LLP
Cooley Godward Kronish LLP